GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elekta AB (OTCPK:EKTAY) » Definitions » Total Liabilities

Elekta AB (Elekta AB) Total Liabilities : $1,977 Mil (As of Jan. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Elekta AB Total Liabilities?

Elekta AB's Total Liabilities for the quarter that ended in Jan. 2024 was $1,977 Mil.

Elekta AB's quarterly Total Liabilities declined from Jul. 2023 ($1,962.15 Mil) to Oct. 2023 ($1,926.83 Mil) but then increased from Oct. 2023 ($1,926.83 Mil) to Jan. 2024 ($1,976.87 Mil).

Elekta AB's annual Total Liabilities declined from Apr. 2021 ($1,958.84 Mil) to Apr. 2022 ($1,819.11 Mil) but then increased from Apr. 2022 ($1,819.11 Mil) to Apr. 2023 ($1,920.59 Mil).


Elekta AB Total Liabilities Historical Data

The historical data trend for Elekta AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elekta AB Total Liabilities Chart

Elekta AB Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,745.93 2,026.48 1,958.84 1,819.11 1,920.59

Elekta AB Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,764.08 1,920.59 1,962.15 1,926.83 1,976.87

Elekta AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Elekta AB's Total Liabilities for the fiscal year that ended in Apr. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1227.823+(620.192+72.572
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1,921

Total Liabilities=Total Assets (A: Apr. 2023 )-Total Equity (A: Apr. 2023 )
=2861.119-940.532
=1,921

Elekta AB's Total Liabilities for the quarter that ended in Jan. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1252.208+(656.512+68.151
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1,977

Total Liabilities=Total Assets (Q: Jan. 2024 )-Total Equity (Q: Jan. 2024 )
=2966.513-989.642
=1,977

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elekta AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Elekta AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Elekta AB (Elekta AB) Business Description

Address
Kungstensgatan 18, Box 7593, Stockholm, SWE, SE-103 93
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company's installed base of more than 5,000 linear accelerators, GammaKnife and Unity platforms, and software is used in more than 6,000 hospitals globally. The company's sales are evenly distributed across geographies, with North and South America accounting for 31%; Europe, the Middle East, and Africa accounting for 35%; and Asia-Pacific contributing the remainder.